StockData
Cytek Biosciences, Inc. logo

Cytek Biosciences, Inc. (CTKB) stock

CTKBNasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 8/308% below fair value
$5.84+0.32 (+5.80%)

Close on Nov 13, 2026Market cap $759.10MP/E –Yield –

Cytek Biosciences profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Cytek Biosciences's profit margin for the twelve months ending Sep 30, 2026 was -39.1%. For fiscal 2025 it was -33.0%, against -3.0% the year before. The highest annual figure on record is 2733.9% in fiscal 2020.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-33.0%−30.0
FY2024Dec 31, 2024-3.0%+3.3
FY2023Dec 31, 2023-6.3%−7.8
FY2022Dec 31, 20221.5%−137.3
FY2021Dec 31, 2021138.8%−2595.2
FY2020Dec 31, 20202733.9%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q3 FY2026Sep 30, 2026-11.5%−1.0
Q2 FY2026Jun 30, 2026-25.3%−13.0
Q1 FY2026Mar 31, 2026-42.7%−15.2
Q4 FY2025Dec 31, 2025-70.9%−57.2
Q3 FY2025Sep 30, 2025-10.5%−1.6
Q2 FY2025Jun 30, 2025-12.2%+6.1
Q1 FY2025Mar 31, 2025-27.5%−35.2
Q1 FY2024Mar 31, 2024-13.8%−17.8
Q2 FY2023Jun 30, 2023-8.8%−7.1
Q1 FY2023Mar 31, 2023-18.4%−12.2
Q4 FY2022Dec 31, 20227.7%+10.7
Q3 FY2022Sep 30, 20224.0%−0.1
Q2 FY2022Jun 30, 2022-1.7%−10.5
Q1 FY2022Mar 31, 2022-6.2%−6.6
Q4 FY2021Dec 31, 2021-3.0%−21.3
Q3 FY2021Sep 30, 20214.1%−21.9
Q2 FY2021Jun 30, 20218.8%−33.6
Q1 FY2021Mar 31, 20210.4%–
Q4 FY2020Dec 31, 202018.3%–
Q3 FY2020Sep 30, 202026.1%–
Q2 FY2020Jun 30, 202042.4%–

More Cytek Biosciences figures

See a number that looks wrong?